Common use of Further License Grants Clause in Contracts

Further License Grants. In addition to the licenses granted in Section 2.1.1 above, at such time, if any, that MUS assigns to Codexis the Subject Agreements (as defined below), then, subject to the terms and conditions of this Agreement, MUS shall concurrently grant to Codexis, licenses under the Enabling Technology and related Know-How, and Product Technology and related Know-How, to the extent necessary for Codexis to allow it to perform its contractual obligations existing as of the date of assignment with regard to such Subject Agreements, for the sole purpose of allowing Codexis to perform such contractual obligations under such agreements. For purposes of this Section 2.1.3, the “Subject Agreements” shall mean (i) the Novo Agreement; (ii) the Collaborative Research and Development Agreement entered by Maxygen, Inc. and Technological Resources Pty Limited effective January 19, 2000, (iii) the Research Agreement entered by Maxygen, Inc. and Chevron U.S.A, Inc. effective October 11, 2000, (iv) the Collaborative Agreement entered by Maxygen, Inc. and Hercules Incorporated effective October 31, 2000; (v) the Collaboration Agreement entered by Maxygen, Inc. and Xxxxxxx-Xxx L.L.C., effective March 19, 2002; (vi) the Research Agreement entered by Maxygen, Inc. and Pfizer, Inc., effective September 13, 2000, as amended prior to the Effective Date of this Agreement; and (vii) the Agreement entered by Maxygen, Inc. and Gist-Brocades B.V., effective March 15, 1999, as amended prior to the Effective Date of this Agreement.

Further License Grants. In addition to the licenses granted in Section 2.1.1 above, at such time, if any, that MUS assigns to Codexis the Subject Agreements (as defined below), then, subject to the terms and conditions of this Agreement, MUS shall concurrently grant to Codexis, licenses under the Enabling Technology and related Know-How, and Product Technology and related Know-How, to the extent necessary for Codexis to allow it to perform its contractual obligations existing as of the date of assignment with regard to such Subject Agreements, for the sole purpose of allowing Codexis to perform such contractual obligations under such agreements. For purposes of this Section 2.1.3, the “Subject Agreements” shall mean (i) the Novo Agreement; (ii) the Collaborative Research and Development Agreement entered by Maxygen, Inc. and Technological Resources Pty Limited effective January 19, 2000, (iii) the Research Agreement entered by Maxygen, Inc. and Chevron U.S.A, Inc. effective October 11, 2000, (iv) the Collaborative Agreement entered by Maxygen, Inc. and Hercules Incorporated effective October 31, 2000; (v) the Collaboration Agreement entered by Maxygen, Inc. and XxxxxxxCxxxxxx-Xxx L.L.C., effective March 19, 2002; (vi) the Research Agreement entered by Maxygen, Inc. and Pfizer, Inc., effective September 13, 2000, as amended prior to the Effective Date of this Agreement; and (vii) the Agreement entered by Maxygen, Inc. and Gist-Brocades B.V., effective March 15, 1999, as amended prior to the Effective Date of this Agreement.